N/A N=150 Intensive Models of HCV Care for Injection Drug Users
Hepatitis C · Medication Adherence
Primary: Electronically Monitored Medication Adherence — 86; 80; 75 Percentage of medication taken
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=107 Interactive Motivational Media for Perinatal Drug Abuse - 3
Substance-Related Disorders
Primary: Number of Participants With Drug Use at 3 Months — 49; 48 participants
N/A N=348 Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Hepatitis C, Chronic
Primary: Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin — 56; 150 participants
N/A N=246 Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
Hepatitis C, Chronic · Substance Abuse, Intravenous
Primary: Number of Drug-substituted Participants Who Achieved Sustained Virological Response (SVR) With PegIntron 1.5 μg/kg/Week and Rebetol (10.6 mg/kg/Day) in Substitution…
Phase 2 N=84 The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
Opioid Dependence
Primary: Percent of Weekly Urine Samples Negative for Opiates — 64.5; 81.3; 71.1; 66.7 percentage of negative urine samples — p=0.48
Phase 3 N=141 Treating Violence-Prone Substance Use Disorder Patients
Substance-related Disorders · Violence
Primary: Addiction Severity Index Legal Composite — .038; .012 units on a scale
Phase 3 N=151 Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
Opioid Use Disorders
Primary: Opioid Use — 6; 12; 7 Participants
N/A N=86 Feasibility of SBIRT-PN
Substance Use · HIV/AIDS · Older Adults
Primary: Number of Participants Ranking Intervention as Acceptable — 9; 5 Participants
N/A N=29 Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
Opioid-use Disorder
Primary: Treatment Retention — 5; 5 Participants — p==0.87
N/A N=21 Effective Treatment of Hepatitis C in Substance Users
Hepatitis C · Opiate Dependence
Primary: Number of Participants With a Sustained Virologic Response (SVR) — 7; 1 participants
Phase 2 N=44 Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Opioid-Related Disorders
Primary: Emax - Maximum Drug Liking — 54.5; 75.0; 72.1; 75.6 score on a scale
N/A N=152 A Therapeutic Workplace to Address Poverty and Substance Use
Substance Use Disorders
Primary: Alcohol Abstinence — 82.8; 60.2 percentage of participants — p=<0.001
Phase 2 N=30 Intermittent Naltrexone Among Polysubstance Users
Methamphetamine · Alcohol
Primary: Feasibility of Retaining Participants in Trial — 100; 86.7 percentage that completed study
N/A N=47 HealthCall-S: A Pilot Study Targeting Concurrent Non-injection Drug Use and Alcohol in HIV Primary Care Clinics
Alcohol or Other Drugs Use
Primary: Mean Number of Days Used Primary Drug (NumDU) — 8.5; 5.0 days
Phase 3 N=17 Abuse Liability of Suboxone Versus Subutex
Opioid-related Disorders
Primary: Drug's Breakpoint — 1200; 10; 1100; 1200 number of clicks on a mouse
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
N/A N=250 Survey to Identify Substance Use in Teenagers and Adolescents
Anesthesia
Primary: Number of Participants With Adolescent and Parent Reported Alcohol, Drug, Vaping and Tobacco Usage — 1; 1; 0; 425 Participants
N/A N=132 Brief Intervention for Justice-Involved Substance Users
Substance Use · Violence
Primary: Percent Days Abstinent — 44; 42 percentage of days abstinent — p=.07
N/A N=720 Building on Needle Exchange to Optimize Prevention & Treatment
Intravenous Drug Usage · HIV/AIDS
Primary: Composite PWID Score (Service Access, Risk Behaviors, Adverse Outcomes) — 5.34; 5.64 units on a scale — p=0.125
N/A N=302 Exercise as a Treatment for Substance Use Disorders Protocol
Stimulant Abuse and Dependence
Primary: Percent Days Abstinent — 90.8; 91.6; 75.5; 77.2 Percentage of Days — p=<0.05
Phase 4 N=225 Linking Infectious and Narcology Care-Part II
HIV Infection · Drug Use
Primary: Undetectable HIV Viral Load at 12 Months — 46.9; 22.7 percentage of participants
Phase 3 N=300 ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence
Alcohol Dependence
Primary: Cumulative Percentage of Participants by Heavy Drinking Rate — 40.8; 47.3; 59.2; 59.5 percentage of participants — p=0.336
Early Phase 1 N=44 Inpatient Single Dose Interventions for Alcohol Use Disorder
Alcohol Use Disorder, Severe
Primary: Rate (%) of 30-day Hospital Re-admission — 3; 2; 7 Participants
Phase 2 N=183 Therapeutic Substance Abuse Treatment in Pregnancy - 1
Alcohol Abuse · Cocaine Abuse · Marijuana Abuse
Primary: Percentage of Days Used Drugs or Alcohol — 18; 21; 6; 7 percentage of days — p=0.88
N/A N=240 HealthCall:Brief Intervention to Reduce Non-injecting Drug Use in HIV Primary Care Clinics
Mental and Behavioral Disorders Due to Harmful Drug Use
Primary: Total Number of Days of Primary Drug Used in the Prior 30 Days — 5.07; 3.61; 4.73 Days
N/A N=5,706 Computerized Substance Use and Depression Screening and Behavioral Treatment in HIV Primary Care
Substance Use Disorders · HIV · Depression
Primary: Change in Mental Health and Substance Use Screening Rates — 2008; 2379 Participants
Phase 2 N=27 ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids
Opiate Dependence
Primary: Slope Change From Baseline for Pupil Size — -0.5540; -0.3607; -0.1410 cm(2)/hr
N/A N=79 Leveraging Technology to Address Unhealthy Drug Use in Primary Care Settings
Addiction
Primary: Receipt of Brief Intervention (BI) for Drug Use at Baseline Visit — 17; 33 Participants
Phase 3 N=27 Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
Heroin Dependence
Primary: Drug Self-administration — 350; 255; 223; 113 Clicks on a computer mouse
N/A N=546 A Randomized Trial of Vaccine Adherence in Young Injection Drug Users
Medication Adherence · Substance Abuse, Intravenous · Risk Behavior
Primary: Vaccine Series Completion — 16; 20; 8; 10 participants